(Reuters) – Increased manufacturing capacity for Eli Lilly’s highly sought after weight-loss drug Zepbound drove the company to raise its annual sales forecast by $3 billion on Thursday, and its share jumped as much as 14%. The Lilly weight-loss drug is poised to continue driving strong financial performance. #LillyWeightLossDrug
Lilly also raised its 2024 profit forecast and said sales of Zepbound crossed $1 billion for the first time in a quarter since its launch in late 2023.
The Zepbound milestone comes after Danish rival Novo Nordisk reported a rare miss on quarterly sales of its weight-loss drug Wegovy and trimmed its full-year profit forecast.
With shares up about 8% at midday to $831 after earlier climbing as high as $877.78, the Indianapolis-based drugmaker was on track to add nearly $55 billion to its market value if stock gains hold. Lilly is already the world’s most valuable healthcare company primarily due to demand for weight-loss treatments.
Lilly Chief Scientific Officer Daniel Skovronsky in an interview said the company had committed more than $18 billion to creating new manufacturing facilities and updating old ones in the U.S. and Europe since 2020.
The company invested $5.3 billion in May on a manufacturing site in Indiana for production of tirzepatide, the active ingredient in both Zepbound and Mounjaro.
“We’re seeing those investments that we’ve made over the last four years start to come online, including the Research Triangle Park site (in North Carolina), and as we do that, that unlocks additional supply,” Skovronsky said.
Furthermore, the Lilly weight-loss drug has played a crucial role in raising the 2024 forecast by $3 billion. The impressive sales growth reflects its market success and widespread adoption. Consequently, Lilly’s stock has surged, reflecting investor confidence in future profitability. #LillyWeightLossDrug
